Our research lab investigates the interactions between the oral microbiome and breast cancer progression. We explore how pathogenic bacteria in the oral cavity impact cancer development, metastasis, and patient outcomes, aiming to reveal microbial contributions to cancer biology. Our approach integrates microbiology, genomics, molecular biology, and bioinformatics to study bacterial pathogens' roles in cancer initiation and progression, as well as their influence on the immune system and tumor microenvironment.
Additionally, we conduct SNP genotyping to identify genetic variants linked to breast cancer susceptibility and treatment response. We also focus on designing phytocompound-based inhibitors for critical enzymes like Aromatase and 17-beta Hydroxysteroid Dehydrogenase, which regulate estrogen synthesis. These inhibitors aim to provide safer, plant-based treatments for breast cancer. Our interdisciplinary research strives to advance cancer prevention and treatment.
Screening SNPs in the CYP19A1 gene to identify breast cancer-related variations and computationally evaluating compounds from Swietenia macrophylla as potential aromatase inhibitors, with the goal of developing targeted therapies for breast cancer.
In collaboration with the Dept of Medical Oncology
Screening and characterizing the virulence factors of Fusobacterium nucleatum in the oral microbiome of breast cancer patients to explore its potential role in cancer development or progression.
In collaboration with the Dept of Medical Oncology
Association of Fusobacterium nucleatum with Breast Cancer Progression and Virulence Factor Profiling in South Indian Patients
This work was accepted, presented and won second prize at the The Rencontres de Quy Nhon VII: International Biology Conference 2024, Vietnam on October 3rd, 2024. Presentation Vietnam Abstract_KiruthikaV
Identification and evaluation of potential 17-beta-hydroxysteroid dehydrogenase (17β-HSD) inhibitors for breast cancer through both in silico and in vitro methods in order to develop and validate novel inhibitors targeting this enzyme to improve breast cancer treatment.
Mallur, Dhrithi Jayasimha, B. Lavanya, Sheshadri S. Temkar, V. Arun, and Benedict C. Paul. "Exploring okra-derived compounds as prospective aromatase inhibitors: a computational study for enhanced breast cancer therapy." Journal of Biomolecular Structure and Dynamics (2024): 1-9.
Temkar, Sheshadri S., Amruta Sridhara, Dhrithi Jayasimha Mallur, Deepak Ishwara Shivaprakash, Divya Iyengar, Nritam Das, and Benedict Paul C. 2024. “Potential Aromatase Inhibitors from Centella Asiatica with Non-Synonymous SNPS - A Computational Approach.” Current Computer-Aided Drug Design 20 (4): 341–58. doi: 10.2174/1573409919666230525151933. PMID: 37231718
For full list of publications, click here